Quick Answer
Coenzyme Q10 Migraine Randomized Trial has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: In addition to its high prevalence and disability burden, migraine is associated with substantial socioeconomic costs, with estimated direct and indirect expenditures of approximately USD 36 billion annually in the United States [].
Key Takeaways
- 01In addition to its high prevalence and disability burden, migraine is associated with substantial socioeconomic costs, with estimated direct and indirect expenditures of approximately USD 36 billion annually in the United States []. [Kozák Márk (2026)]
- 02Clinically, migraine is characterized by recurrent attacks of moderate-to-severe headache lasting 4–72 h, typically unilateral and pulsating, aggravated by routine physical activity, and frequently accompanied by photophobia and phonophobia; in a substantial subset of patients, attacks are associated with reversible focal neurological symptoms called aura. [Kozák Márk (2026)]
- 036 7 8 9 10 11 12 2 13 14 10 15 16 Helicobacter pylori The most common gastrointestinal disorders associated with migraine are irritable bowel syndrome (IBS) (reported in up to 50% of patients with migraine []), inflammatory bowel disease (IBD) [,,], gastroesophageal reflux disease (GERD) [], functional dyspepsia [,], cyclic vomiting syndrome [], peptic ulcers andinfections [,]. [Kozák Márk (2026)]
- 041 2 3 4 2 3 5 Migraine is a prevalent primary headache disorder with significant morbidity and rising prevalence, affecting around 14% of the global population []. [Kozák Márk (2026)]
The current Migaku evidence database contains 2 reusable source documents for Coenzyme Q10 Migraine Randomized Trial. This answer focuses on strength of evidence and what the studies can or cannot prove.
- In addition to its high prevalence and disability burden, migraine is associated with substantial socioeconomic costs, with estimated direct and indirect expenditures of approximately USD 36 billion annually in the United States []. [Kozák Márk (2026); evidence level 3]
- Clinically, migraine is characterized by recurrent attacks of moderate-to-severe headache lasting 4–72 h, typically unilateral and pulsating, aggravated by routine physical activity, and frequently accompanied by photophobia and phonophobia; in a substantial subset of patients, attacks are associated with reversible focal neurological symptoms called aura. [Kozák Márk (2026); evidence level 3]
- 6 7 8 9 10 11 12 2 13 14 10 15 16 Helicobacter pylori The most common gastrointestinal disorders associated with migraine are irritable bowel syndrome (IBS) (reported in up to 50% of patients with migraine []), inflammatory bowel disease (IBD) [,,], gastroesophageal reflux disease (GERD) [], functional dyspepsia [,], cyclic vomiting syndrome [], peptic ulcers andinfections [,]. [Kozák Márk (2026); evidence level 3]
- 1 2 3 4 2 3 5 Migraine is a prevalent primary headache disorder with significant morbidity and rising prevalence, affecting around 14% of the global population []. [Kozák Márk (2026); evidence level 3]
- 1 2 3 4 5 Migraine is a chronic, disabling neurovascular disorder characterized by recurrent episodes of moderate-to-severe headache, typically unilateral and pulsating in quality, and frequently associated with nausea, vomiting, photophobia, and phonophobia. [Santangelo Domenico (2026); evidence level 3]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources